Pakistan releases results of clinical study on TCM treatment of COVID-19

2022-06-11 0 By

Pakistani health authorities on Monday released the results of a clinical trial of traditional Chinese medicine to treat COVID-19, Reuters reported On Monday.Meanwhile, the South Asian country is facing a fifth wave of the disease caused by the Omikron variant.The press conference of Jinhua Qinggan granules was jointly held by The International Institute of Chemical and Life Sciences (ICCBS) and Juxichang (Beijing) Pharmaceutical Co., LTD.According to People’s Daily, since April 2020, The University of Karachi and Hunan University of Medicine have been collaborating to conduct clinical studies on the efficacy and safety of Jinhua Qinggan Granule in the treatment of COVID-19 under the china-Pakistan Chinese Medicine Cooperation Center jointly established by the two sides.Reuters noted that Jinhua Qinggan Granule, a traditional Chinese medicine produced by China Juxichang (Beijing) Pharmaceutical Co., Is already being used in China to treat COVID-19 patients.Professor Iqbal Chaudhry, director of the International Institute of Chemical and Life Sciences (ICCBS) at the University of Karachi, which is conducting the clinical trial in Pakistan, told reporters at the meeting:”Since the TCM was tested on patients infected with different COVID-19 variants, we expect it to be effective against omicron and other variants.”Raza Shah, the lead investigator of the clinical trial, said the tests, conducted on 300 patients treated at home, were effective for mild-to-moderate cases of COVID-19, with an effective rate of about 82.67 percent.The project was previously approved by Pakistan’s Drug Control Agency, Reuters said.Pakistan reported 4,340 confirmed cases of COVID-19 on Monday, the highest daily number of new cases recorded in three months.Karachi, the country’s largest city, recorded a positive rate — the percentage of positive tests — of 39.39 per cent over the weekend, the highest so far.The country’s National Command and Operations Centre for COVID-19 Response (NCOC) tweeted on Monday that “confirmed cases in Pakistan have increased by 170% and deaths by 62% in the past seven days.”According to the official website of Juxichang (Beijing) Pharmaceutical Co., LTD., Zhang Boli, academician of the Chinese Academy of Engineering, said, “Current studies have proved that Jinhua Qinggan is effective in the treatment of mild and ordinary COVID-19, which is reflected in the time of fever reduction, improvement of symptoms and absorption of inflammation, and the proportion of mild cases to severe is also reduced.”The clinical study conducted by the Beijing You ‘an Hospital team found that compared with the Western medicine group, the nucleic acid conversion days of The Jinhua Qinggan granule group (7.27±3.71 days) were significantly lower than the nucleic acid conversion days of the control group (9.80±4.37 days). Meanwhile,The leukocyte normalization rate (90.2% VS 80.4%) and lymphocyte normalization rate (74.5% VS 64.7%) were increased.Source: Global Times Hot spot